TITLE

Prevalence of Clinical Symptoms Associated with Highly Active Antiretroviral Therapy in the Women's Interagency HIV Study

AUTHOR(S)
Silverberg, Michael J.; Gore, Mary Elizabeth; French, Audrey L.; Gandhi, Monica; Glesby, Marshall J.; Kovacs, Andrea; Wilson, Tracey E.; Young, Mary A.; Gange, Stephen J.
PUB. DATE
September 2004
SOURCE
Clinical Infectious Diseases;9/1/2004, Vol. 39 Issue 5, p717
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. The extended use of antiretroviral drugs among human immunodeficiency virus (HIV)-seropositive individuals underscores the need for a comprehensive evaluation of therapy-associated clinical symptoms. Methods. Beginning in April 2000, 364 HIV-seronegative and 1256 HIV-seropositive women enrolled in a multicenter cohort study reported clinical symptoms that included abdominal pain, diarrhea, anorexia, nausea and/or vomiting, myalgias, fatigue, fever, body fat redistribution, dizziness, headaches, paresthesias, xerostomia, nephrolithiasis, and rash. We examined the prevalence of symptoms with respect to HIV infection and the use of highly active antiretroviral therapy (HAART), using data-correlation models. Results. in the 6 months before a study visit, 49% of HIV-seronegative women, 67% of HIV-seropositive women not receiving therapy, and 69% of HIV-seropositive women receiving HAART reported any clinical symptom. The odds ratios (ORs) for reporting any symptom were 1.4 (95% confidence interval [CI], 1.1-1.8) for women who changed HAART regimens and 0.9 (95% CI, 0.7-1.1) for women reporting stable HAART use, compared with those reporting no therapy use. Significant findings (P < .05) for particular symptoms were an increased odds of diarrhea, nausea and/or vomiting, body fat redistribution, myalgias, and paresthesias, when data for women who changed HAART regimens were compared with those for women not receiving therapy. The OR for reporting any symptom was 1.5 (95% CI, 1.2-1.9) for women who switched HAART regimens and 1.6 (95% CI, 1.3-1.9) for women who discontinued HAART, compared with those reporting stable HAART use. Conclusions. Our findings confirm the high prevalence of clinical symptoms among HIV-seropositive women who changed HAART regimens. The high prevalence of symptoms among HIV-seronegative women and HIV- seropositive women not receiving therapy demonstrates that caution should be used when attributing the occurrence of symptoms entirely to HAART.
ACCESSION #
14174284

 

Related Articles

  • The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome. Clarke, S M; Mulcahy, F; Healy, C M; Condon, S; Butler, K M // International Journal of STD & AIDS;Apr2000, Vol. 11 Issue 4, p220 

    Antiretroviral therapy (ART) and Caesarean section (CS) delivery significantly reduce the risk of vertically transmitted HIV infection. Attention must focus on determining the optimal management strategy for HIV-positive pregnancies. Guidelines must reflect not only the activity and tolerability...

  • Primary HIV-1 infection during pregnancy: high rate of HIV-1 MTCT in a cohort of patients in southern Brazil. Nielsen-Saines, Karin; Melo, Marineide; Varella, Ivana; Fonseca, Rosana; Lira, Rita; Turella, Maria Lourdes; Canti, Ivete; Campello, Claudio; Moreira, Ana Maria; Santos, Breno Riegel // Retrovirology;2008 Supplement 1, Vol. 5, Special section p1 

    Background Mother to Child HIV-1 Transmission (MTCT) is infrequent among women who receive highly active antiretroviral therapy (HAART) throughout pregnancy. Women who undergo primary HIV-1 infection during pregnancy, however are at high risk of perinatal transmission. Materials and methods MTCT...

  • Nevirapine Regimen Reduces Risk of HIV Transmission From Breast-Feeding--at Least in the Short Term. Doskoch, P. // International Family Planning Perspectives;Sep2008, Vol. 34 Issue 3, p150 

    The article looks at the short term effects of the anti-retroviral drug nevirapine on instances of HIV transmission from breast feeding. A regimen of nevirapine was found to reduce HIV transmission in babies who are breast-fed for six weeks following birth. The author considers the need for...

  • Innovative policy to prevent mother-to-child transmission of HIV shows positive impact.  // Washington Informer;3/7/2013, Vol. 48 Issue 21, p18 

    The article reports that in 2011, the Malawi Ministry of Health has introduced a new treatment option for pregnant or breast-feeding women infected with HIV, known as Option B+, which offers these women lifelong antiretroviral treatment (ART) regardless of their stage of HIV infection. It also...

  • An unusual case of hyperlactataemia in a neonate. Nirupam, Nilay; Nangia, Sushma; Kumar, Ajay; Saili, Arvind // International Journal of STD & AIDS;Dec2013, Vol. 24 Issue 12, p986 

    We report a HIV uninfected neonate born to HIV positive mother, who had tachypnoea at birth. On investigations, he was found to have hyperlactataemia. All the secondary causes for elevated lactate were ruled out. Hyperlactataemia was attributed to the perinatal exposure, to maternal...

  • CCR2 Genotype and Disease Progression in a Treated Population of HIV Type 1--Infected Women. Philpott, Sean; Burger, Harold; Tarwater, Patrick M.; Ming Lu; Gange, Stephen J.; Anastos, Kathryn; Mardge Cohen; Greenblatt, Ruth M.; Kovacs, Andrea; Minkoff, Howard; Young, Mary; Miotti, Paolo; Dupuis, Michelle; Weiser, Barbara // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p861 

    Both antiretroviral therapy and the human co receptor polymorphism CCR2-V641 slow progression of human immunodeficiency virus type I (HIV-1) disease. To examine the effect of V641 on disease progression in patients receiving therapy, we determined CCR2 genotypes in the Women's Interagency HW...

  • ECHO: Antiretroviral drugs confuse universal antenatal blood screens.  // Sexually Transmitted Infections;Aug2005, Vol. 81 Issue 4, p305 

    The article cites a study, which reveals that antiretroviral drugs confuse universal antenatal blood screens. It is reported that all women infected with HIV should have their hemoglobin concentrations recorded before they start antiretroviral drug treatment to avoid later suspicion antenatally...

  • Undetectable HIV-1 viral load in the fluid of bullous skin lesion in a patient receiving highly active anti retroviral therapy. Tattevin, Pierre; Maillard, Anne; Tribut, Olivier; Sa├»kali, Emilie; Arvieux, Cedric; Michelet, Christian // International Journal of STD & AIDS;May2008, Vol. 19 Issue 5, p357 

    Health-care workers may be exposed to bullous fluid while caring for bullous skin diseases in HIV-infected patients. Given that bullous fluid is a filtrate of plasma, it may be assumed that HIV viral load (VL) in bullous fluid is close to plasma VL. This was documented in a patient who had...

  • Lopinavir + ritonavir followed by nevirapine "optimal ART strategy.".  // PharmacoEconomics & Outcomes News;7/1/2006, Issue 506, p6 

    This article discusses research being done on an optimal treatment strategy for HIV-infected South African women. It references a study by C. B. Holmes et al published in the June 15, 2006 issue of "Clinical Infectious Diseases." Information is presented on the model developed for the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics